Serum Zinc-α2-Glycoprotein Correlates with Adiposity, Triglycerides, and the Key Components of the Metabolic Syndrome in Chinese Subjects

Yeung, Dennis C.Y.; Lam, Karen S.L.; Wang, Yudong; Tso, Annette W.K.; Xu, Aimin

doi:10.1210/jc.2009-0058

Cited by 78 publications

(106 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zinc-α-2 glycoprotein presented higher values only in obese individuals who had not been subjected to bariatric surgery. In another study, higher serum levels of this protein were found for obese individuals than for those with normal weight [45]. Consequently, the increased expression of this protein in the saliva of obese individuals, observed in our study, may reflect higher levels of the protein in the blood.…”

Section: Discussionsupporting

confidence: 60%

Changes in the salivary protein profile of morbidly obese women either previously subjected to bariatric surgery or not

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

Changes in the salivary protein profile of morbidly obese women either previously subjected to bariatric surgery or not

et al. 2015

View full text Add to dashboard Cite

“…However, the data on serum ZAG levels in relation to obesity are inconsistent, being reported as decreased, 52,55 unchanged 57 or increased. 58 Circulating ZAG levels have been shown to be negatively 56 or positively 58 correlated with insulin and the insulin resistance indices. It is possible that adipose tissue-derived ZAG is more important locally through its autocrine/paracrine actions.…”

Section: Zag Expression and Body Fat Massmentioning

confidence: 99%

Zinc-α2-glycoprotein: an adipokine modulator of body fat mass?

et al. 2010

View full text Add to dashboard Cite

The importance of white adipose tissue in the control of energy balance is now firmly recognized. In addition to fuel storage, adipocytes secrete an array of proteins factors (adipokines), which regulate multiple physiological and metabolic processes as well as influence body fat accumulation. Zinc-a2-glycoprotein (ZAG), a lipid mobilizing factor initially characterized as a tumor product associated with cachexia, has recently been identified as a novel adipokine. Although the exact role of ZAG in adipose tissue remains to be clarified, there is evidence that ZAG expression appears to be inversely related to adiposity, being upregulated in cachexia whereas reduced in obesity. Investigations on the regulation of ZAG give insights into its potential function in adipose tissue with a link to lipid mobilization and an anti-inflammatory action. Recent work shows that ZAG stimulates adiponectin secretion by human adipocytes. Data from genetic studies suggest that ZAG may be a candidate gene for body weight regulation; this is supported by the demonstration that ZAG-knockout mice are susceptible to weight gain, whereas transgenic mice overexpressing ZAG exhibit weight loss. The present review summarizes these new perspectives of ZAG and the potential mechanisms by which it might modulate adipose tissue mass and function.

show abstract

“…ZAG has been shown to act as a lipid-mobilizing factor (6). Treatment with ZAG stimulates lipolysis in isolated mouse and human adipocytes, and it selectively reduces body fat in both with adiposity, triglycerides (TG), and the key components of metabolic syndrome (8). Additionally, ZAG expression and protein levels have been reported to be down-regulated in subcutaneous and visceral adipose tissue of obese men and women in comparison with the lean controls (9).…”

Section: Introductionmentioning

confidence: 99%

Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial

Tian¹,

Liang²,

Liu³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Zinc-a 2 -glycoprotein (ZAG) has recently been characterized as a potent metabolic regulator. However, the effects of anti-diabetic agents on circulating ZAG levels in humans remain largely unknown. To explore the possible mechanisms by which the dipeptidyl peptidase-IV (DPP-IV) inhibitor improves insulin resistance, we investigated the effect of sitagliptin, a DPP-IV inhibitor, on circulating cytokine levels in newly diagnosed type 2 diabetes (nT2DM) patients. Design and methods: A subset of 141 subjects with nT2DM were assigned to receive placebo (nZ47) or sitagliptin (nZ94) for 3 months. Before and after treatment, subjects received a 75 g oral glucose tolerance test, euglycemic-hyperinsulinemic clamp (EHC), and measurement of ZAG and adiponectin (ADI) concentrations. Results: Circulating ZAG levels were lower in nT2DM than in control individuals (P!0.01). After 3 months of sitagliptin treatment, HbA1c, fasting plasma glucose, postprandial glucose, 2-h insulin after glucose overload, triglycerides, and homeostasis model assessment of insulin resistance (HOMA-IR) were decreased significantly compared with pre-treatment (P!0.05 or P!0.01), whereas the glucose infusion rate during the stable period of the clamp (M values) during EHC were significantly increased (P!0.01). In addition, circulating ZAG and ADI concentrations were significantly increased along with improved glucose metabolism and insulin sensitivity compared with pre-treatment (both P!0.01) and the change of ZAG (DZAG) was positively associated with DADI, DHOMA-IR, DBMI, Dfasting insulin and negatively associated with D tumor necrosis factor-a (TNF-a). Furthermore, sitagliptin treatment resulted in significantly lowered plasma TNF-a level (P!0.05). Conclusion: A low level of circulating ZAG is associated with insulin resistance and sitagliptin treatment significantly increases circulating ZAG levels. These observations have implications in relation to the mode of action of the DPP-IV inhibitor as an insulin sensitizing agent.

show abstract

Serum Zinc-α2-Glycoprotein Correlates with Adiposity, Triglycerides, and the Key Components of the Metabolic Syndrome in Chinese Subjects

Abstract: ZAG might be involved in the pathogenesis of obesity-related metabolic disorders in humans and thus warrants further investigation.

Cited by 78 publications

References 34 publications

Changes in the salivary protein profile of morbidly obese women either previously subjected to bariatric surgery or not

Changes in the salivary protein profile of morbidly obese women either previously subjected to bariatric surgery or not

Zinc-α2-glycoprotein: an adipokine modulator of body fat mass?

Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial

Contact Info

Product

Resources

About